According to investing7's report on July 31, the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for Cytisinicline, a treatment for nicotine e-cigarette cessation. This medication is developed by the American pharmaceutical company Achieve Life Sciences. If approved, it would be the first drug specifically designed for nicotine e-cigarette cessation. It is important to note that Cytisinicline is currently an experimental product and has not received any approval for use by the FDA in the United States.
Golden Chrysanthemum Alkaloid is a plant-based alkaloid with high affinity for binding to nicotine acetylcholine receptors. By interacting with nicotine receptors in the brain, it reduces the severity of withdrawal symptoms and decreases the reward and satisfaction associated with nicotine products, aiding in the treatment of nicotine addiction resulting from smoking and e-cigarette cessation.
According to sources, the company's ORCA-V1 phase II clinical trial compared the effects of lobeline and a placebo on 160 adult e-cigarette users. The experiment showed that participants treated with lobeline were 2.6 times more likely to successfully quit smoking compared to those using the placebo. Achieve Corporation plans to hold a phase II final meeting with the FDA's multidisciplinary team by the end of this year to discuss the next steps.
Data shows that over 11 million adults in the United States use e-cigarettes, with approximately 2.1 million middle and high school students also using them. Currently, the FDA has not approved any specific treatment methods to help individuals quit nicotine e-cigarettes.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
